Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size study, by Type (Intravenous, Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecasts 2022-2032

Description

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market is valued approximately at USD 788.91 million in 2023 and is anticipated to grow with a healthy growth rate of more than 12.48% over the forecast period 2024-2032. Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. This debilitating condition leads to the degeneration of voluntary muscles, resulting in loss of motor function and eventual respiratory failure. The increasing incidence of ALS, unmet treatment needs, and rising research funding for neurodegenerative disease therapeutics are key drivers propelling the market growth. The aging population and the development of novel drugs further contribute to the expansion of the ALS treatment market.

Despite significant advancements, the high cost of treatment and stringent regulatory guidelines pose substantial challenges. However, continuous efforts to develop cost-effective treatments and improve access to affordable therapies are crucial to addressing these challenges. The market is also witnessing opportunities with the advent of novel therapies and increased awareness about ALS.

The key regions considered for the global Amyotrophic Lateral Sclerosis (ALS) Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market in terms of revenue. The market growth in the region is being attributed to factors including high incidence of ALS compared to other regions. Also, advanced healthcare infrastructure: Established healthcare infrastructure allows for early diagnosis, better management of ALS, and access to specialized treatments. The presence of leading pharmaceutical companies and research institutions fuels innovation in ALS treatments, leading to a wider range of options for patients. The presence of leading companies such as Pfizer, Sangamo Therapeutics, and Celgene, along with increased investments in patient awareness initiatives, propels market growth in this region. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by increased public and healthcare professional awareness of ALS leads to earlier diagnosis and a greater need for treatment options. As the population ages in Asia Pacific, the number of people susceptible to ALS naturally increases, creating a larger patient pool. Also, with developing economies in the region, spending on healthcare is rising, making ALS treatments more accessible to patients. Growing recognition of the benefits of early intervention is propelling the market for ALS treatments that can slow disease progression.

Major market players included in this report are:

AB Science SA
Alkem Laboratories Ltd.
Apotex Inc.
Aquestive Therapeutics Inc.
Biogen Inc.
Brainstorm Cell Therapeutics Inc.
CORESTEM Inc.
Cytokinetics Inc.
Dr Reddys Laboratories Ltd.
Eledon Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Italfarmaco Holding SPA
Medindia Health
Mitsubishi Chemical Group Corp.
Otsuka Holdings Co. Ltd.

The detailed segments and sub-segment of the market are explained below:

By Type

Intravenous
Oral

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Executive Summary

1.1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type
- 1.3.2. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics

3.1. Market Drivers
- 3.1.1. High research funding
- 3.1.2. Increasing aging population
- 3.1.3. Rising incidence of ALS
3.2. Market Challenges
- 3.2.1. High treatment costs
- 3.2.2. Stringent regulatory guidelines
3.3. Market Opportunities
- 3.3.1. Development of novel drugs
- 3.3.2. Increased awareness about ALS

Chapter 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size & Forecasts by Type 2022-2032

5.1. Segment Dashboard
5.2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.2.1. Intravenous
- 5.2.2. Oral

Chapter 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size & Forecasts by Distribution Channel 2022-2032

6.1. Segment Dashboard
6.2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.2.1. Hospital Pharmacies
- 6.2.2. Retail Pharmacies
- 6.2.3. Online Pharmacies

Chapter 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size & Forecasts by Region 2022-2032

7.1. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.1.1. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  - 7.1.1.1. Type breakdown size & forecasts, 2022-2032
  - 7.1.1.2. Distribution Channel breakdown size & forecasts, 2022-2032
- 7.1.2. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market
7.2. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.2.1. U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.2.2. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.2.3. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.2.4. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.2.5. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.2.6. Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market
7.3. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.3.1. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.3.2. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.3.3. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.3.4. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.3.5. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.3.6. Rest of Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market
7.4. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.4.1. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.4.2. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.4.3. Rest of Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market
7.5. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.5.1. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.5.2. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market
- 7.5.3. Rest of Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market

Chapter 8. Competitive Intelligence

8.1. Key Company SWOT Analysis
8.2. Top Market Strategies
8.3. Company Profiles
- 8.3.1. Alkem Laboratories Ltd.
  - 8.3.1.1. Key Information
  - 8.3.1.2. Overview
  - 8.3.1.3. Financial (Subject to Data Availability)
  - 8.3.1.4. Product Summary
  - 8.3.1.5. Market Strategies
- 8.3.2. Apotex Inc.
- 8.3.3. Aquestive Therapeutics Inc.
- 8.3.4. Brainstorm Cell Therapeutics Inc.
- 8.3.5. CORESTEM Inc.
- 8.3.6. Dr Reddys Laboratories Ltd.
- 8.3.7. Eledon Pharmaceuticals Inc.
- 8.3.8. Ionis Pharmaceuticals Inc.
- 8.3.9. Italfarmaco Holding SPA
- 8.3.10. Medindia Health
- 8.3.11. Mitsubishi Chemical Group Corp.
- 8.3.12. Otsuka Holdings Co. Ltd.
- 8.3.13. AB Science SA
- 8.3.14. Biogen Inc.
- 8.3.15. Cytokinetics Inc

Chapter 9. Research Process

9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
9.2. Research Attributes